Cobimetinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Cobimetinib manufacturing plant. It encompasses all critical aspects necessary for Cobimetinib production, including the cost of Cobimetinib production, Cobimetinib plant cost, Cobimetinib production costs, and the overall Cobimetinib manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Cobimetinib production plant.

These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cobimetinib is an anticancer medication used to treat a type of skin cancer called melanoma when it has spread to other parts of the body or cannot be completely removed by surgery. It functions by blocking a protein called mitogen-activated extracellular kinase (MEK) that is involved in the growth and spread of cancer cells.

Cobimetinib is also used in combination with vemurafenib (a targeted therapy that works by blocking a mutated protein called BRAF). It is also utilized to treat an uncommon type of blood cancer called histiocytic neoplasms in adults. It is also utilized to treat an uncommon type of blood cancer called histiocytic neoplasms in adults.

The procurement of Cobimetinib is influenced by its application in the pharmaceutical and medical industries as an anticancer drug used to treat melanoma or skin cancer. The widespread occurrence of skin cancer is significantly increasing the demand for Cobimetinib.

According to clinical research, combining Cobimetinib with Vemurafenib increases overall survival (OS) and progression-free survival (PFS) more than using Vemurafenib alone. This makes the combination a favored treatment option, which drives its market expansion. Its market is further driven by the better tolerability and safety records of the combination therapy as compared to other drugs of its class, which enhances its market position.

The drug’s utility in conditions apart from melanoma, such as aiding in the treatment of colorectal cancer, also contributes to its market adoption.Overall, industrial Cobimetinib procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of skin cancer, combination therapy, improvement in survival rates, better safety profile and tolerability, and regulatory approvals.

Raw Material for Cobimetinib Production

According to the Cobimetinib manufacturing plant project report, the key raw material used in the production of Cobimetinib includes tert-butyl 2-(3-hydroxyazetidin-3-yl)piperidine-1-carboxylate.

Manufacturing Process of Cobimetinib

The extensive Cobimetinib production cost report consists of the following major industrial manufacturing process:

• Production from tert-butyl 2-(3-hydroxyazetidin-3-yl)piperidine-1-carboxylate: The manufacturing process of Cobimetinib starts with the reaction of the starting compound with L-tartaric acid to give enantiopure S-enantiomer as the corresponding diastereomeric tartrate salt. The compound is subjected to peptide coupling with 3,4-difluoro-2-(2-fluoro-4-iodo-anilino) benzoic acid to form the Boc-protected Cobimetinib. Finally, Cobimetinib is produced via acid-mediated removal of the Boc-protective group.

Cobimetinib, commercially known as Cotellic, is a white to off-white crystalline powder having the molecular formula C21H21F3IN3O2 and a molecular weight of 531.3 g/mol. It has an estimated water solubility of 0.0422 mg/mL. It has a log P value of 3.35. The value of its dissociation constant, pKa, is 13.37.

It is an inhibitor of mitogen-activated protein kinase and is used alongside vemurafenib to treat patients with metastatic or incurable melanoma. It belongs to the group of piperidines, as well as N-acylazetidine, tertiary alcohol, aromatic amine, difluorobenzene, secondary amino compounds, and organoiodine compounds.